Gilgamesh Pharmaceuticals
-54%
est. 2Y upside i
Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…
Rank
#2707
Sector
Biotechnology
Est. Liquidity
~4Y
Data Quality
Data: MediumGilgamesh Pharmaceuticals, now operating as Gilgamesh Pharma Inc. after successfully spinning off its lead asset for up to $1.2 billion, presents a moderate upside opportunity for a job seeker.
Last updated: March 10, 2026
Gilgamesh Pharma Inc. successfully advances GM-1020 or its ibogaine analog through late-stage clinical trials, demonstrating strong efficacy and safety. This leads to a significant strategic partnership or acquisition by a major pharmaceutical company, valuing the new entity at $200M+, driven by the large TAM for psychiatric diseases.
Gilgamesh Pharma Inc. continues to progress its pipeline, with GM-1020 moving successfully through Phase 2b/3. The company secures additional funding at a higher valuation, maintaining its position as an innovative player in the neuroscience biotech space, leading to an eventual exit at around $110M.
Clinical trials for GM-1020 or other lead candidates face setbacks or fail to meet endpoints, or the company struggles to secure sufficient follow-on funding in a competitive market. This results in a down round or a distressed sale, significantly eroding common stock value, potentially to $30M or less.
Preference Stack Risk
moderateInvestors in the new Gilgamesh Pharma Inc. hold $6.09 million in liquidation preferences, which represents 8.12% of the assumed current $75 million valuation for the new entity. The original Gilgamesh Pharmaceuticals had raised approximately $89 million before the spin-off.
Dilution Risk
highAs a clinical-stage biotechnology company, Gilgamesh Pharma Inc. will require substantial additional funding rounds to advance its pipeline, leading to significant future dilution for current equity holders.
Secondary Liquidity
noneGilgamesh stock is not currently traded in the private markets, with no active buyers or sellers at this time.
Questions to Ask at the Interview
Strategic questions based on Gilgamesh Pharmaceuticals's data — designed to show you've done your homework.
- 1
“Given the successful monetization of bretisilocin, how is Gilgamesh Pharma Inc. prioritizing and funding the development of its remaining pipeline, specifically GM-1020 and the ibogaine analog, to achieve similar significant milestones?”
- 2
“With large pharmaceutical companies like AbbVie actively acquiring assets in the neuroscience and psychedelic space, what is Gilgamesh Pharma Inc.'s long-term strategy for either remaining independent or pursuing further strategic partnerships/acquisitions for its other novel chemical entities?”
- 3
“Considering the recent $6.09 million funding round, what is the company's projected runway, and what are the key milestones Gilgamesh Pharma Inc. aims to achieve before its next capital raise or liquidity event?”
Community
Valuation Sentiment
Our model estimates -54% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.